Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sutent in intermediate-2 or high-risk MDS or CMML
NCT00451048Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Feb 2007
- Primary completion
- Sep 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of sunitinib in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), sponsored by National Cancer Institute. Started Feb 2007; status: completed.
02
Drugs
sunitinib
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)
Beyond the preview
Go deeper on NCT00451048.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00451048.